oral sodium phenylbutyrate

DRUG3 trials

Sponsors

National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), University of California, San Diego

Conditions

Gastric CancerHead and Neck CancerLeukemiaLymphomaLymphoproliferative DisorderUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

CompletedNCT00002909

National Cancer Institute (NCI)Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific

Start: 1997-02-28Updated: 2013-02-05

Phase 2

Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

CompletedNCT00006240

National Heart, Lung, and Blood Institute (NHLBI)Leukemia

Start: 2000-10-31End: 2001-08-31Updated: 2015-04-28

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

WithdrawnNCT00387530

University of California, San DiegoGastric Cancer, Head and Neck Cancer, Lymphoma +1

Start: 2006-05-31End: 2008-01-31Updated: 2019-08-02